View in EDS

Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial.

Saved in:
Bibliographic Details
Title: Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial.
Authors: Ramalingam, Suresh S1 ssramal@emory.edu, Jänne, Pasi A2, Mok, Tony3, O'Byrne, Kenneth4, Boyer, Michael J5, Von Pawel, Joachim6, Pluzanski, Adam7, Shtivelband, Mikhail8, Docampo, Lara Iglesias9, Bennouna, Jaafar10, Zhang, Hui11, Liang, Jane Q12, Doherty, Jim P13, Taylor, Ian12, Mather, Cecile B12, Goldberg, Zelanna14, O'Connell, Joseph13, Paz-Ares, Luis15
Source: Lancet Oncology. Nov2014, Vol. 15 Issue 12, p1369-1378. 10p.
Database: Academic Search Ultimate
Description
ISSN:14702045
DOI:10.1016/S1470-2045(14)70452-8